Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection (Q39760748)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

cervical intraepithelial neoplasia

1 reference

based on heuristic

inferred from title

object named as

Marc Steben

8

0 references

Cosette M Wheeler

2

object named as

Cosette M Wheeler

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Suzanne Marie Garland

4

object named as

Suzanne M Garland

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Richard M Haupt

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Darron R Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Daron G Ferris

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Jorma A Paavonen

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Matti O Lehtinen

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Elmar A Joura

9

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Katherine E D Giacoletti

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

David R Radley

11

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Margaret K James

12

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Alfred J Saah

13

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Heather L Sings

14

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

FUTURE I and II Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

13 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

2632-2642

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Management of women who test positive for high-risk types of human papillomavirus: the HART study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

The Bethesda System 2001: an update of new terminology for gynecologic cytology

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Immune responses to human papillomavirus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25940

21 January 2018

Identifiers

10.1002/IJC.25940

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39760748&oldid=2090027884"